These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 29607190)

  • 1. Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy.
    Kurman JS; Murgu SD
    J Thorac Dis; 2018 Feb; 10(2):1124-1128. PubMed ID: 29607190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer.
    Zhou R; Tong F; Zhang Y; Zhang R; Bin Y; Zhang S; Yang N; Dong X
    Front Oncol; 2023; 13():1231094. PubMed ID: 38023206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics.
    Arasanz H; Zuazo M; Bocanegra A; Gato M; Martínez-Aguillo M; Morilla I; Fernández G; Hernández B; López P; Alberdi N; Hernández C; Chocarro L; Teijeira L; Vera R; Kochan G; Escors D
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32033028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease.
    Yildirim HC; Guven DC; Aktepe OH; Taban H; Yilmaz F; Yasar S; Aksoy S; Erman M; Kilickap S; Yalcin S
    J Clin Med; 2022 Sep; 11(17):. PubMed ID: 36079101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
    Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A; Leighl N; Joshua AM; Butler MO; Hogg D; Chappell MA; Soultani L; Chow K; Boujos S; Bedard PL
    Cancer; 2019 Apr; 125(8):1341-1349. PubMed ID: 30768786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperprogression: A novel response pattern under immunotherapy.
    Han XJ; Alu A; Xiao YN; Wei YQ; Wei XW
    Clin Transl Med; 2020 Sep; 10(5):e167. PubMed ID: 32997401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
    Zhou L; Zhang M; Li R; Xue J; Lu Y
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3269-3279. PubMed ID: 32857178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.
    Lin M; Vanneste BGL; Yu Q; Chen Z; Peng J; Cai X
    Transl Lung Cancer Res; 2021 Jul; 10(7):3276-3291. PubMed ID: 34430364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations.
    Ferrara R; Signorelli D; Proto C; Prelaj A; Garassino MC; Lo Russo G
    Transl Lung Cancer Res; 2021 Jun; 10(6):2955-2969. PubMed ID: 34295690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study.
    Tanaka Y; Matsubara O; Asada K; Muramatsu A; Suzuki M; Shirai T
    Respir Med Case Rep; 2019; 28():100885. PubMed ID: 31249779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.
    Wong DJ; Lee J; Choo SP; Thng CH; Hennedige T
    Immunotherapy; 2019 Feb; 11(3):167-175. PubMed ID: 30730278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.
    Shen P; Han L; Ba X; Qin K; Tu S
    Front Pharmacol; 2021; 12():678409. PubMed ID: 34290608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
    Kim JY; Lee KH; Kang J; Borcoman E; Saada-Bouzid E; Kronbichler A; Hong SH; de Rezende LFM; Ogino S; Keum N; Song M; Luchini C; van der Vliet HJ; Shin JI; Gamerith G
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31683809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors.
    Kasparian S; Gentille C; Burns E; Bernicker EH
    JTO Clin Res Rep; 2020 Jun; 1(2):100017. PubMed ID: 34589924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
    Tunali I; Gray JE; Qi J; Abdalah M; Jeong DK; Guvenis A; Gillies RJ; Schabath MB
    Lung Cancer; 2019 Mar; 129():75-79. PubMed ID: 30797495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprogression as a distinct outcome after immunotherapy.
    Fuentes-Antrás J; Provencio M; Díaz-Rubio E
    Cancer Treat Rev; 2018 Nov; 70():16-21. PubMed ID: 30053725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy.
    Gomes da Morais AL; de Miguel M; Cardenas JM; Calvo E
    Cancer Treat Rev; 2020 Dec; 91():102116. PubMed ID: 33157360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is hyperprogressive disease a specific phenomenom of immunotherapy?
    Brambilla M; Russo GL; Ferrara R; Manglaviti S; Garassino MC; Occhipinti M
    Explor Target Antitumor Ther; 2020; 1(6):427-433. PubMed ID: 36046388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy.
    Frelaut M; du Rusquec P; de Moura A; Le Tourneau C; Borcoman E
    BioDrugs; 2020 Aug; 34(4):463-476. PubMed ID: 32394415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.